Positron emission tomography AnnexinA5 Logan method Distribution volume ratio Enhanced permeability and retention effects Purpose: The uptakes of radiolabel led AnnexinA5 (AnxA5) and a size-matched control protein in experimental tumours were evaluated by kinetic analyses and compared with standard uptake values (SUVs) to investigate whether the method of analysis may impact on the conclusions that can be drawn. Procedures: PET scans of the 11 C-labelled proteins performed in untreated and doxorubicin-treated mice with head and neck carcinoma xenografts were retrospectively analysed. The appropriateness of using the Logan graphical analyses for reversibly binding radiotracers in these models was evaluated and confirmed. Distribution volume ratios (DVRs) of the regions of interest to reference muscle tissue were compared to those based on the image-derived input function from arterial blood. SUVs were calculated in the same individuals. Results: DVRs based on reference muscle tissue gave results similar to those based on the arterial blood and may be preferred since they are simpler to calculate. In the inter-group comparisons of baseline versus chemotherapy treatment or AnxA5 versus control protein, differences in DVR quantifications had a 20-to 40-fold higher statistical significance than differences in SUVs. As quantified using the control protein, the amount of free ligand in the vascular space of tumours may be large due to enhanced permeability and retention (EPR) contributions at baseline and affected during treatment, which has implications for quantifications of the specifically bound radioligand.
Introduction
Non-invasive molecular imaging methods in positron and single photon emission tomography (PET and SPECT, respectively) are usually tested pre-clinically prior to implementation in human subjects. Since the development of dedicated cameras with optimised spatial resolution [1] , imaging strategies are more and more frequently optimized in rodents [2, 3] . Methods for analysing the results obtained in rodents generally follow those that have been used for many years in humans, and radiotracer behaviour is most often characterized as normalized uptakes in tissues. Kinetic modeling can be used to quantitate physiological parameters that are more sensitive for showing individual variations, but the techniques that have been developed for use in humans need to be adapted to and validated for the animals/strains and the applications studied [4, 5] .
In this study we examine the use of a method for quantifying the behaviour in tumour-bearing mice of a medium-sized (36 kDa) protein AnnexinA5 (AnxA5) labelled with positron-emitting carbon-11 through a C-terminal selenocysteine tag (ST) [6] . The biological basis for the molecular imaging strategy is that cells externalize phosphatidylserine (PS) when they die, especially through apoptosis and necrosis, and that the endogenous human protein AnxA5 binds selectively and with high affinity (1 nM) to PS [7] . Therefore, noninvasive observation of the binding of radiolabeled AnxA5 to tissues with externalized PS should enable the localization and estimation of cell death under different conditions. The uptake of radiolabeled AnxA5-based probes has been used preclinically as well as clinically as a marker for spontaneous and induced cell death in e.g. ischemia and in tumours [8] . However, considerable work has been required to optimize strategies for site-specifically labeling the protein with 99m Tc for SPECT imaging, and more recently, with the PET nuclides 18 F, 68 Ga, 124 I and 11 C (see e.g. [9] and references therein). Differences in levels of baseline cell death versus therapy-induced changes at discrete times have often been difficult to detect or accurately quantify. These pharmacokinetic and timing issues are related to both the protein and the processes being studied and have limited a wide utilization of this AnxA5-based imaging. Recently a human PS-targeting antibody 89 Zrlabeled PGN635 was introduced as a new strategy for imaging dynamic apoptotic processes since the antibody probes have plasma half-lives on the order of weeks and therefore might be able to image cumulative apoptosis occuring over time [10] . Alternatively probes for visualizing other biomarkers of cell death in vivo are also being evaluated [9] . Since the optimal imaging strategy has not yet been agreed upon, further investigations on the underlying factors affecting the quantification of these imaging probes are motivated. Most previous AnxA5-based studies have been primarily evaluated in the region of interest (ROI) using static imaging at relatively late times and the standard assessment methods (see e.g. [11] ) widely used in clinical imaging. For rapidly localizing probes, it can also be feasible and sometimes desirable to dynamically measure concentrations of radioactivity in an ROI and in reference tissues and observe changes as time activity curves (TACs) over time after radiotracer administration. Both methods can be sufficient to describe the behaviour of the tracer if, for example, the uptake in an ROI is significantly different from that in a baseline study or in a reference tissue and the in vivo behaviour of the radiotracer and its metabolism have been characterized and accounted for. That may, however, be more difficult to do in peripheral tissues since radiometabolites are not necessarily stopped by tissue barriers (like in the brain) and may therefore contribute to the non-specific uptake. Furthermore, in tumours an enhanced permeability and retention (EPR) caused by leaky blood vessels and compromised lymphatic drainage [12] can increase the amount of tracer accumulating due to non-binding mechanisms.
Compartmental analyses of dynamically acquired data are considered to be more accurate and, in some cases, necessary for appropriately describing radiotracer behaviour [13] [14] [15] , though they are often not considered practical in high throughput clinical imaging. These methods have historically been developed for quantifying receptor ligands in the brain (e.g. [16, 17] ). Applications in peripheral tumours have been reported (e.g. [18, 19] ), though very seldom for macromolecular probes (e.g. [20] ) and, to our knowledge, not previously with AnxA5-based imaging probes.
In compartmental analyses, the free, non-specifically and specifically bound tracers are separated into well-delineated compartments (see e.g. [21] ). However, near-equilibrium between non-specifically bound and the free tracer is rapidly achieved. This justifies omitting one compartment, leaving two-compartment models which are more easily analysed. Combinations of in-and outflow parameters which define the specific compartment enable the determination of macro parameters such as the binding potential and the distribution volume [22, 23] . Contributions from free tracer must be estimated, usually from the metabolite-corrected radioactivity in arterial blood. Continuous collection of blood samples is, however, invasive and is not possible when the available blood volume is a limiting factor as in studies in small animals. Therefore, alternative graphical methods have been developed that instead of arterial blood use a reference tissue devoid of specifically bound tracer to assess the contribution from the free tracer [24, 25] . The reliability of these graphical methods must be demonstrated for each tracer and each reference tissue. When used in studies in peripheral tissues this verification procedure can be even more complex due to the wider size range of the tracers (small molecules to peptides, proteins or antibodies and their fragments) that can be utilized in peripheral organs and the complexity in the factors affecting their retention in different tissues.
Here a graphical analysis method is used to describe the behaviour of the 11 C-labeled AnxA5 in experimental tumours and reference muscle tissue. In order to assess non-specific contributions related to the vascularity of the tumours, we used a control protein of similar size to the AnxA5 but with no apparent binding behaviour: mutated thioredoxin fused with green fluorescent protein (mTrx-GFP) which was also similarly labelled with carbon-11 [6] . The macro parameter results for these two proteins are compared to those obtained by conventional uptake assessments in non-treated and chemotherapy-treated tumourbearing mice.
Materials and methods
Experiments were performed in accordance with national legislation on laboratory animals' protection and were approved by the local ethics committee for animal research. The animals used in this trial were permitted food ad libitum until the morning of the PET procedures.
Radioligands
The preparations of the ligands used here, H 6 -AnxA5-ST and its size-matched control protein, H 6 -mTrx-GFP-ST, have been presented elsewhere [26] . In brief, these proteins were expressed with a his-tag on the N-terminus to facilitate protein purification and on the C-terminus with a selenocysteine tag to enable site-specific labelling with positron-emitting carbon-11 ( 11 C) labeled methyl iodide (t 1/2 ≈ 20 min) under relatively mild conditions. Due to the short half-life of the radionuclide, PET studies are restricted to approximately one hour scan time. If the tracers bind reversibly, they should reach semi-equilibrium during that hour. AnxA5 does bind reversibly to the phosphatidylserine externalized after induction of cell death [27] . Uptake of the [methyl-11 C]-H 6 -AnxA5-ST-CH 3 in head and neck carcinoma xenografts has been observed to reach a maximum at around 30 min, plateau and tend to decrease slightly at the end of a 60 min scan [6] . These characteristics indicated that the compartmental methods for reversible [28, 29] rather than irreversible tracers [30] could be more appropriate, which is further evaluated here (see results 3.2).
In vivo microPET studies
The PET camera used was the microPET Focus 120 (Concorde, Siemens), which has been previously extensively evaluated [31] . The field of view is 7.6 and 10 cm for axial and trans-axial dimensions, respectively. Data were continuously collected in list mode, corrected for dead time, randoms and physical decay and histogrammed as follows: 3 seconds × 20 frames, 150 seconds × 8 frames and 293 seconds × 8 frames. Subsequent recontruction was conducted using ordered subset expectation maximisation in 2 dimensions (OSEM2D) employing 4 iterations and 16 subsets. The software used to analyse the PET data and perform the compartmental analyses was the Inveon Research Workplace (IRW) developed by Siemens. When additional data analyses were required, the Matrix Laboratory (MatLab) software was used. Whole body ROIs were analysed to examine whether all radioactivity is accounted for in the measurements (i.e. assess whether there are losses due to excretion and exhalation). The uptake of radioactivity in blood, reference tissue and tumour regions was examined to see if secular or transient equilibrium conditions were satisfied during the one hour period after the bolus tracer administration.
Tumour model
Severe combined immunodeficiency (SCID) mice were inoculated with head and neck carcinoma (FaDu) cells on the right shoulder, well separated from other tissues with appreciable uptake of the radiotracers in order to minimize spillover effects. Xenografts were allowed to grow for about ten days until the smallest diameter (by palpation) was at least three times the full width half maximum (FWHM) of the camera (range 4-9 mm) to minimize partial volume effects. As controls, five untreated tumour-bearing animals were examined in the microPET using [methyl-
(Anx base ) and five with [methyl-11 C]-H 6 -mTrx-GFP-ST-CH 3 (GFP base ).
Additionally, five tumour-bearing mice were treated with the chemotherapeutic agent doxorubicin and, 72 h after a single administration, were scanned with [methyl-
(Anx treated ). The radioactivity injected, 0.192-0.373 MBq per gram body weight, was determined by measuring the syringe before and after the injection as well as lines and other possible residual radioactivities. Effective specific radioactivity was about 5000-10000 MBq/μmol, based on the total unlabeled protein used in the labeling experiments. About 1 nmole of protein was injected per animal. Statistical gains would have been expected if these studies had been performed longitudinally and each treated animal was its own control. However, in this case it was a priority to be able to correlate the estimations of cell death induction revealed in these tumours with PET with ex vivo tissue and serum analyses, which have been previously reported [6] . In the present study the methods for quantifying the PET data for these inter-individual comparisons are analysed in more depth.
Conventional uptake measurements
Conventional uptake is measured and evaluated by the widely used standard uptake value (SUV). The SUV is defined as
SUV¼ radiotracer concentration injected activity=NormalisationFactor ð1Þ
in which the normalisation used here was to body weight. SUV was computed for every reconstructed time frame. When the last 25 minutes were used to include more data, the mean uptake was affected slightly, ≈ 2%, by the tendency of [methyl-11 C]-H 6 -AnxA5-ST-CH 3 uptake to decrease after 35 min [6] . Therefore only SUVs calculated at semi-equilibrium, 30 to 35 minutes after the PET scanning was initiated, were used in the comparisons.
Kinetic modelling
The distribution volume (DV) and binding potential (BP) [23] are the macro parameters most often estimated when describing the tissue uptake of a radioligand. The BP relates the specific binding of the radioligand to a target to some other reference concentration. The DV relates the concentration of a radioligand in a tissue to the total concentration in plasma. Target tissues may contain radioligand that is specifically bound, non-specifically bound or free in tissue water. The non-displaceable BP (BP ND ) and the distribution volume ratio (DVR) relate the corresponding radioligand quantifications in a receptor-rich ROI to those in a receptor-free reference tissue. We previously [6] have described the tissue uptake of the radioligands studied here using BP ND . However subsequent analyses have indicated that DVR might be a more appropriate parameter since the non-specific uptake in the tumour tissue may be quite large, may vary from one subject to another and also due to treatment effects.
Here we use the commercially-supplied (IRW) software to calculate and validate the DVR obtained by the Logan graphical method [25] . This method hereafter, referred to as Logan ref , was originally developed for describing the binding of radioligands to central neuroreceptors. Logan ref is a data-driven method. In other words it does not a priori assume a specific number of compartments. Macro parameters of interest are determined by the gradient of the fit of certain measured points. The fit is adjusted so that as many points as possible are included while simultaneously minimising the associated chi-squared value. The number of points that were used in each fit may therefore vary. Here we required at least seven points.
The apppropriateness of the tissue chosen as a reference tissue must be verified. This is done by observing some intrinsic compartmental parameter ratio when changing compartmental set-up, e.g.
which was used here. We assumed that if there are no extra in-/ outflows, i.e. no additional compartments, this ratio will not be significantly different from unity when comparing a one-compartment to a two-compartment model. This assumption was further confirmed by performing an F-test (MatLab).
To validate the use of a reference tissue method in the peripheral tissues, the DVR was estimated by the Logan method using an arterial blood input [28] , hereafter referred to as Logan art . Both Logan ref and Logan art assume that the reference region, the arterial blood and the impulse response function reach a linear relationship for t N t´(here t´was 35 minutes). The method with arterial input yields the DV. By subsequently dividing the DV of the target ROI by the DV of the reference tissue, the DVR is obtained. The calculation of the DVR by the IRW software was initially verified by also performing the calculations with MatLab.
Three different image-based ROIs were used: the tumour, the reference region and the arterial blood. The radioactivity concentration in the arterial blood throughout the dynamic PET scan was obtained from a left heart chamber ROI, which was delineated in a 3 second interval during the first ten seconds. The volume of this ROI was approximately 20 mm 3 . Spatial resolution was improved and partial volume effects somewhat controlled by using iterative reconstructions [32] . Iterations in OSEM were perfomed until no significant improvement could be observed in the resulting image. The minimum tumour and reference tissue dimensions included in the study were 3-7 times the resolution. Further partial volume corrections could have been achieved by filtering [33] . However valuable information may be lost during filtering, and this could potentially have a large impact on the statistics of small ROIs in mouse imaging. Bias due to movement could not be corrected by gating, since appropriate sensors for mice are not readily available. However, the tumour and the reference region were located on the shoulder and thigh, respectively, where motions due to breathing and heart beating were expected to have a low impact. The heart ROI was drawn using pixels as centrally located in the left heart chamber as possible. The tumour ROI was drawn when considerable uptake of radioactivity was observed, in this case in the time frames after 35 min. First, a so-called primary ROI, based on the dimensions of excised tissues determined ex vivo, was drawn manually for each separate tumour and fitted to the tumour dimensions in the sagittal, coronal and trans-axial planes of the images. Secondary ROIs were then created by applying intensity thresholds to the tumour inside the primary ROI in order to minimize subjective interpretations and increase reproducibility [34] . This secondary ROI was used in the subsequent analyses. Appropriate shapes of the ROI TACs were confirmed by visual inspection (one and the same observer). Noticeable shifts in body positioning during the study led to exclusion from the analyses. The ROI for the reference tissue was drawn over both hamstring muscles, and the reference tissue most consistent with the requirements given above (Eq. (2) ≈ 1) was chosen. The size of this ROI was similar to that of the tumour. Intensity thresholding was also applied to the reference ROI. Regions with more intense uptake and assumed to be joints were omitted using two-sided thresholding.
In 
Statistical analysis & significance assessment
A QQ-plot (Matlab) analysis of the macro parameter was performed, and the results were not consistent with a normal distribution. Therefore the t-test was not employed. Instead, a Wilcoxon two sample rank sum test was used to test the null hypothesis that there was no difference between the groups for the calculated SUVs and DVRs for the doxorubicin treated animals versus the untreated animals for the 11 C-labeled H 6 -AnxA5-ST and H 6 -mTrx-GFP-ST.
Cohen's d calculated as analysed N 98% of the injected radioactivity was accounted for over the 60 min scan (data not shown). This decrease is interpreted to be due to exhalation of volatile metabolites. The total amount of radioactivity in the body is essentially the same for the two tracers throughout the scan. On a regional level, the only tissue uptake differences previously observed were a higher maximum radioactivity level in the kidneys and higher molecular weight 11 C-labeled protein excreted to the urine after the AnxA5 administrations [6] . Radioactivity in the blood and plasma was also previously shown to be primarily (≈ 95%) in high molecular weight forms up to 40 min [26] , and therefore metabolite contributions were not further considered here.
Results

Confirmation of radioactivity accountability by examinations of whole body ROIs
Test of equilibrium at t N t' and validation of the use of muscle tissue as a reference tissue
An image demonstrating the uptake of [methyl- 11 C]-H 6 -AnxA5-ST-CH 3 and the tumour ROI delineation is given in Fig. 2A . In order to determine if and at which time the uptake of [methyl-11 C]-H 6 -AnxA5-ST-CH 3 satisfied secular or transient equilibrium conditions after the bolus tracer administration [36] and the appropriateness of using muscle tissue as a reference tissue, the time profiles for concentrations of radioactivity (measured in SUVs) in different regions were examined in one typical animal. After the initial distribution phase, the concentrations in the arterial blood tended to level off from approximately 35 min to the end of the scan (Fig. 2B) , with a slope during this period calculated to be approximately − 0.0455. The ratio of C muscle / C artblood , reflecting the variation of non-specific and free radioligand in the chosen reference tissue over time, increased slowly but tended to level off with a slope of 0.0007 during the last 20 min (Fig. 2C ). The ratio of C tumour /C muscle increased between 5 and 20 min, levelled off before decreasing slightly to a plateau with a slope of − 0.0079 between 40 and 60 min (Fig. 2D) . Thus the concentrations in the region containing the specific binding and that of the reference tissue reach an approximate secular equilibrium during the last 20 minutes of the 60 min scans. Furthermore the reference tissue TAC was subtracted from the tumour TAC to show "specific" uptake of the radioactivity (e.g. [37] ). The TAC tumour -TAC ref plateaued from around 30-35 min generally until the end of the experiment with, in several animals, a slight tendency to decrease. As a further control, all baseline tumours were also analysed using the Patlak graphical method for irreversibly binding tracers [24] . The residuals between the fitted line and the measured data points did not result in horizontal lines (i.e. the plots were non-linear), which indicated that the data are not adequately described by this method for irreversible tracers. All these results together support the use of the Logan method for reversible tracer kinetics. An example of the Logan plots obtained for baseline investigations with the 11 C-labeled AnxA5 is shown in Fig. 3A . The DVRs for the 11 Clabeled AnxA5 and mTrx-GFP probes in the FaDu xenografts were calculated using the Logan graphical method with either the arterial blood or the reference muscle tissue. The reference tissue was validated and approved using both Eq. (2) and the F-test. The Logan art gave slightly different DVRs than the Logan ref on an individual level, as shown in Fig. 3B . However, the differences are not significant on the group level. Therefore, we conclude that the Logan ref method, which is simpler to perform, is also acceptable in extracerebral analyses of these two tracers in this model.
Comparison of tracer uptake estimations by conventional uptake (SUV) and macro parameter determination (Logan ref ) methods
To investigate the capability of the macro parameter method to distinguish small differences in tracer uptake between groups, the DVR in non-vs. doxorubicin-treated FaDu-bearing mice was calculated by the Logan ref method and compared with those determined by the conventional SUV method (Fig. 4) . The SUV analysis indicated a trend toward an increase in [methyl- 11 C]-H 6 -AnxA5-ST-CH 3 uptake after doxorubicin treatment (d = 1.2), but the differences between groups were only statistically significant (i.e. p b 0.05) when the DVR Fig. 1 . Whole body ROI comparisons accounting for the entire radioactivity in the body after administration of the two tracers used in this study. The uptake was here normalised to the maximum uptake and multiplied by 100. The error bars represent standard deviation of the mean.
(d = 2.5, p = 0.0079) was calculated. The significance is improved more than twenty times compared to the SUV results.
Comparison of DVRs for [methyl-11 C]-H 6 -AnxA5-ST-CH 3 and [methyl-11 C]-H 6 -mTrx-GFP-ST-CH 3
The mean regressions gave the mean DVRs, for the labeled AnxA5 and mTrx-GFP as 2.03 and 2.16, respectively (Fig. 3B) . The difference between the two is not statistically significant (p = 0.3). There is a slightly greater spread in the regression lines for labeled mTrx-GFP, but the profiles were surprisingly quite similar for the targeting and non-targeting proteins. This analysis allows an estimation of the EPR effect on the retention of both tracers in the target tissue. Since the DVR is ≈ 2.1, the tumour tissue has a nearly two-fold larger concentration of radioactivity than that in the reference region. Furthermore, DVRs for the AnxA5 and mTrx-GFP are on the same level, which indicates that any specific binding at baseline for the [ 11 C] AnxA5-ST is not separable from the uptake due to the EPR effects. Since 11 C-labeled mTrx-GFP shows the non-specific uptake due to EPR effects, we also may have a method for observing whether there are changes in these effects due to treatment. In Fig. 5 the differences between 11 C-labeled AnxA5 uptake in treated animals vs. 
Discussion
In this study we have compared the use of conventional SUV analyses to a more involved kinetic analysis for assessing the uptake and retention of intermediate-sized AnxA5-based protein radiotracer and its size-matched control in untreated and doxorubicin-treated subcutaneous peripheral tumours in SCID mice. We found that the statistical significance of inter-group comparisons was much higher (≥20-fold) using the macro parameter method compared to the SUV analyses. Statistical gains of this magnitude could potentially have a very large impact, particularly in studies in which differences between groups or conditions are very small. SUV measurements are made at a time interval after equilibrium has been achieved. Here the interval used was at 30-35 minutes, since the tracer uptake thereafter tended to decrease and noise at late times increased. Quantifications performed at specific, short time intervals can potentially be influenced by unknown or uncontrolled individual physiological variations, and this may have contributed to the lower statistical certainty achieved here in the inter-group SUV comparisons ( Fig. 4) . The macro parameter evaluations, on the other hand, utilize data over a larger time interval from the dynamic scan after the semiequilibrium was achieved. The goodness of the fit of the regression to the data included was confirmed by the chi-squared value, thereby providing an objective test of the individual inclusion criteria. This can be particularly valuable for monitoring changes in radioactivity distributions when multiple factors may be affecting them as during, for example, therapeutic protocols. In describing an ideal, isolated system, the influences of a given parameter can be examined by varying a specific parameter while all other parameters are kept constant. This is not possible when working with less ideal systems, like the biological processes involved here, in which several other parameters may and do vary at the same time. The use of ratios, like the distribution volume ratios or binding potentials of a target to a reference region obtained from the graphical analyses, can instead be used to minimize bias that may occur due to other contributing but uncontrolled influences.
In preclinical imaging in mice it is difficult to accurately determine concentrations in the blood since very little blood can be taken from these small animals throughout the entire scan. When instead using image-derived data from the heart to determine concentrations, there are very few voxels available, and accurately quantifying the concentrations can be difficult [38] . Furthermore, artefacts due to breathing and heart movement cannot be minimized in mice by gating, since appropriate equipment is not available. Thus the uptake curves will be less continuous and the distribution volumes less well defined, which probably contributed to the spread for the DVRs determined by Logan art in Fig. 3 .
A specific uptake at baseline of [methyl-11 C]-H 6 -AnxA5-ST-CH 3
could not be estimated since essentially the same mean DVR was obtained for the non-binding, size-matched control, [methyl-
11
C]-H 6 -mTrx-GFP-ST-CH 3 . In addition, these mean DVRs are greater than one, which indicates appreciable EPR effects on the tracer uptake, even though these effects have previously been said to become significant for macromolecules above molecular weights of 40 kDa [39] . Our study indicates that the degree to which these effects contribute to the uptake of intermediate to high molecular weight tracers needs to be examined when validating the radioligand behaviour in experimental models. To our knowledge, this can only be done by using a control ligand that is as similar to the targeting protein in size and other physicochemical properties as possible. Comparing radiotracer uptakes in two different tumour models with different target levels or in tumours in different mouse strains will not per se account also for possible underlying EPR effects on the tracer uptake, unless vascularity and other aspects of the tumour microenvironments are also shown to be essentially identical. Binding potentials can also be obtained from the Logan graphical analyses by subtracting one from the DVR (BP ND = DVR-1). In quantifying neuroreceptor ligands, it is recognized that the BP can only be used as a descriptor as long as the reference tissue has negligible target densities. When using these techniques to model tracer behaviour in tumours, the differences in vascular properties of the reference and tumour tissues must also be taken into account. We therefore suggest that it may be more appropriate to use DVR than the BP ND to describe the uptake of these larger protein ligands that may be leaking into but clearing slowly from the tumour.
The physician's view of the operational difficulties and practical problems associated with different strategies for collecting and analysing PET data in the clinic has recently been vivaciously and provocatively discussed by Galli et al. [40] . Admittedly, the use of optimized static imaging protocols and analyses using SUVs has had a tremendous impact on facilitating the clinical use of PET. However, there is a danger that widespread acceptance and use of these streamlined protocols can block needs to probe in more detail the information that can be obtained with the molecular imaging probes when the results are not giving a clear-cut "yes" or "no". So what are the implications, if any, of the results of this study for the way in which AnxA5-or potentially other radiolabelled probe-based molecular imaging is used to study induced cell death in tumours?
Firstly, it should be pointed out that this inter-group comparison included only a few individuals in each group and that only one tumour type and one type of therapy were being examined. It was far beyond the scope of this study to include enough investigations to generalize the findings to all tumour types and all types of therapy. On the contrary, the goal was quite the opposite: to illustrate that, on an individual level (as is the case in clinical imaging), the underlying pathophysiology and the pharmacological effects of therapy will most certainly be affecting the rates of probe uptake and deposition in and elimination from tumour tissue in manners that are far more complex than increases and decreases in tracer concentrations that solely reflect changes in the specific binding of the tracer. Additionally, moderate changes in tracer uptake from one scan to another in the same individual may not be detected with statistical significance by so-called conventional methods of analysis. Considerable levels of uptake of radiolabelled AnxA5 in untreated tumours have previously been interpreted to indicate basal on-going apoptosis in the tissue [41] . However, our studies demonstrate that AnxA5 uptake may be strongly influenced by EPR effects. These effects are most certainly different for different tumour types [42] . They can vary at different stages of tumour progression and most definitely throughout successful therapy. The EPR effects should be estimated instead of predicted, at least until enough observations (in early clinical trials?) have been made to be able to make predictions. Furthermore, many anti-cancer treatments also have effects on blood flow, and/or the tumour vasculature and these effects may or may not coincide with the induced cell death [43] . To be sure that changes in labelled probe uptakes are due to changes in target expressions, effects on the vasculature must also be accounted for during the cell death imaging.
Here we have used a size-matched control protein to, as closely as possible, estimate the extent of the non-binding contributions on the tracer uptake. It is not likely that this technique can be used in the clinic, but is rather more appropriate for studies in preclinical trials before translating the knowledge gained to improve clinical protocols. Other strategies for measuring vascularity in tumours have been discussed [44] . These may also be easier to test first in preclinical studies like this one, since multiple tracers and multiple imaging sessions can be logistically difficult in a clinical setting. Using relatively rapidly clearing radiotracers like those used here could facilitate such studies so the different parameters would be measured in as close to the same time interval as possible.
Secondly, as pointed out in the introduction, disappointment with experiences of AnxA5-based imaging of induced cell death has led to the examination of even larger imaging probes to obtain cumulative measures of PS externalization over days and the use of other probes targeting other molecular targets important in apoptosis. We suggest, based on our results, that these studies also need to be closely coupled to other measures of vascular contributions to the tracer uptake, retention and elimination from the tumour tissue.
Thirdly, since bioengineering is affording more and more intermediate-sized probes for targeting specific processes, it is important to critically examine how the imaging data obtained with these radiolabeled probes might be analyzed. We have shown that performing dynamic scans and kinetic analyses can be essential for revealing e.g. small differences in therapeutic effects. We also show that it is important to identify other factors behind the radiotracer localizations, particularly in tissue with compromised vasculature and lymphatics, like the tumors studied here. Performing these kinds of analyses in preclinical settings as a first line of analysis can potentially contribute to a better understanding of how similar techniques might or might not be implemented clinically.
Conclusions
Our findings indicate that use of Logan graphical analyses for reversibly binding tracers can be utilized to describe the behaviour of [methyl-
11
C]-H 6 -AnxA5-ST-CH 3 in peripheral head and neck xenografts in mice and that muscle tissue can be used as the reference tissue. Furthermore, evaluations of this intermediate-sized tracer in peripheral tumour tissues need to take into account the non-specific uptake due to EPR effects and also their changes during disease progression or therapy. Since the level of specific binding of radiolabelled AnxA5 uptake in the tumours is small, the more complex macro parameter-based methods were required for finding differences in inter-group comparisons. Here statistical significance was achieved when the DVRs but not when the SUVs were compared (p b 0.008 and p N 0.05, respectively).
